ArticleAdvanced biology2026
Therapeutic Osteoinductive Potential of Saposhnikovia divaricata Schischkin in a Mouse Drill-Hole Bone Defect Model.
Article in Advanced biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Bone fracture healing requires coordinated osteoclast-mediated resorption and osteoblast-driven formation. Saposhnikovia divaricata Schischkin (SDS) is a traditional East Asian medicine with anti-inflammatory and immunomodulatory activities, but its role in bone regeneration remains unclear. This study evaluated the osteogenic potential of SDS using integrated in vitro, in vivo, and in silico approaches. Mouse-derived osteoblasts were treated with SDS, and cell viability, alkaline phosphatase (ALP) activity, and mineralization were assessed by CCK-8, ALP assay, and Alizarin Red O staining. A femoral drill-hole injury model was established in C57BL/6 mice, followed by oral administration of SDS (100, 200, or 400 mg/kg). Bone healing was evaluated by micro-computed tomography and histological analyses. SDS enhanced osteoblast viability, ALP activity, mineral deposition, and osteogenic marker expression in vitro. In vivo, SDS increased bone volume fraction and bone mineral density at 1 week after injury, accompanied by reduced TRAP-positive osteoclasts and increased osteocalcin staining. Molecular docking predicted favorable interactions between major chromone-derived constituents of SDS and the bone-related proteins RUNX2 and RANK. Collectively, these findings suggest that SDS may promote cellular processes associated with early bone repair and warrant further investigation into its mechanisms and long-term therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.